| Renal Cell Carcinoma
Temsirolimus - Temsirolimus vs Welireg
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Temsirolimus vs Welireg with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWelireg has a higher rate of injection site reactions vs Temsirolimus based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Welireg but not Temsirolimus, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Temsirolimus
Welireg
At A Glance
IV infusion
Once weekly
mTOR inhibitor
Oral
Once daily
HIF-2α inhibitor
Indications
- Renal Cell Carcinoma
- Von Hippel-Lindau Syndrome
- Renal Cell Carcinoma
- Pheochromocytoma
- Paraganglioma
Dosing
Advanced Renal Cell Carcinoma 25 mg administered as an intravenous infusion over a 30-60 minute period once weekly; continue until disease progression or unacceptable toxicity. Premedicate with IV diphenhydramine 25-50 mg approximately 30 minutes before each dose.
Dose Modification - Hepatic Impairment Reduce dose to 15 mg/week in patients with mild hepatic impairment (bilirubin >1-1.5x ULN or AST >ULN but bilirubin <=ULN); contraindicated if bilirubin >1.5x ULN.
Dose Modification - Strong CYP3A4 Inhibitors Avoid concomitant use; if unavoidable, reduce dose to 12.5 mg/week and allow approximately 1-week washout after inhibitor discontinuation before returning to prior dose.
Dose Modification - Strong CYP3A4 Inducers Avoid concomitant use; if unavoidable, increase dose from 25 mg/week up to 50 mg/week, then return to prior dose once inducer is discontinued.
Dose Modification - Toxicity Hold for ANC or platelet nadirs meeting threshold criteria or NCI CTCAE grade >=3 adverse reactions; once resolved to grade <=2, restart at dose reduced by 5 mg/week to no lower than 15 mg/week.
Von Hippel-Lindau Syndrome Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Renal Cell Carcinoma Adults: 120 mg orally once daily.
Pheochromocytoma Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Paraganglioma Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Contraindications
- Bilirubin >1.5x ULN
—
Adverse Reactions
Most common (>=30%) clinical adverse reactions Rash, asthenia, mucositis, nausea, edema, anorexia
Most common (>=30%) laboratory abnormalities Anemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, lymphopenia, elevated alkaline phosphatase, elevated serum creatinine, hypophosphatemia, thrombocytopenia, elevated AST, leukopenia
Serious Hypersensitivity/infusion reactions, hepatic impairment, hyperglycemia/glucose intolerance, infections, interstitial lung disease, hyperlipidemia, bowel perforation, renal failure, wound healing complications, intracerebral hemorrhage
Postmarketing Angioedema, rhabdomyolysis, Stevens-Johnson Syndrome, complex regional pain syndrome (reflex sympathetic dystrophy), pancreatitis, cholecystitis, cholelithiasis, extravasation reactions (swelling, pain, warmth, erythema)
Most common (>=25%) Decreased hemoglobin, fatigue, increased creatinine, headache, dizziness, increased glucose, nausea, musculoskeletal pain, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, increased aspartate aminotransferase, anemia, dyspnea, increased calcium, decreased leukocytes, increased alkaline phosphatase.
Serious Anemia, hypoxia, hemorrhage, pneumonia, pleural effusion, pyelonephritis, hypertension, retinal detachment, central retinal vein occlusion, anaphylaxis reaction.
Postmarketing Not reported in label.
Pharmacology
Temsirolimus binds to the intracellular protein FKBP-12, and the resulting protein-drug complex inhibits mTOR (mammalian target of rapamycin), blocking its ability to phosphorylate downstream effectors p70S6k and S6 ribosomal protein, leading to G1 growth arrest in tumor cells and reduced levels of HIF-1, HIF-2 alpha, and vascular endothelial growth factor.
Belzutifan is a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor that binds to HIF-2α and blocks its interaction with HIF-1β, leading to reduced transcription of HIF-2α target genes associated with cellular proliferation, angiogenesis, and tumor growth.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Temsirolimus
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Welireg
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Temsirolimus
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Welireg
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Temsirolimus
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Welireg
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Temsirolimus.
$5/fillfill
Welireg Co-Pay Coupon Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TemsirolimusView full Temsirolimus profile
WeliregView full Welireg profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.